Eli Lilly | GenomeWeb

Eli Lilly

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.    

Thermo Fisher Scientific, Illumina, Eli Lilly, Celgene, and Roche/Genentech have committed their expertise and funding to build a lung cancer registry.

In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.

Lilly decided to stop developing the drug in 2012, but Denovo thinks it can identify a subset of genetically defined patients that can benefit from the drug.

NEW YORK (GenomeWeb) — Biomarker development firm Denovo Biopharma has acquired the late-stage oncology drug enzastaurin from Eli Lilly and Company, and plans to use its genotyping platform to uncover a genomic marker or markers that can support new clinical trials advancing the drug for a genomi

NEW YORK (GenomeWeb) — As part of its quest to become a catch-all provider of tools and technologies for molecular diagnostic and especially companion diagnostic development, Qiagen has added another molecular analysis platform to its portfolio.

Originally published June 3.
NEW YORK (GenomeWeb) – Data from two large studies that tested the efficacy of widely used targeted drugs in molecularly defined breast cancer and colorectal cancer populations failed to show superiority of one therapeutic strategy over another.

This article has been updated from a previous version as Qiagen clarified an earlier statement regarding its acquisition of PrimeraDx.

NEW YORK (GenomeWeb News) – The New York Economic Development Corporation said today it has launched an initiative that will inject $100 million into life sciences startup companies located in the city through a mix of money from city government, life sciences companies, and venture capital partn

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.